The SMA Market: Assessing The Unknowns
Treatment Progress Leads To New Challenges In Spinal Muscular Atrophy
The introductions of Spinraza and Zolgensma in SMA offer new insights into how to address neurodegenerative diseases. But more real world evidence is needed.
You may also be interested in...
High price tag, thin evidence of clinical efficacy for Exondys 51 result in low score from ICER, but a re-do is almost certain when confirmatory data on eteplirsen are released.
Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.
Rather than blame employees for ignoring 397 product complaints, Teligent should have fixed complaint handling system, US FDA warning letter says.